Acral melanoma (AM) is a rare subtype of cutaneous malignant melanoma (MM) found on acral skin, primarily on the soles of the feet. Although rare, it is the most common subtype of MM found in patients of African or East Asian ethnicity and has a poor prognosis, often because of the more advanced stage of presentation at diagnosis. The pathogenesis of AM is unclear, but genetic alterations, including mutations in BRAF, NRAS, and KIT have been implicated. Early diagnosis of AM is important for a better prognosis, but its identification is often challenging, leading to easy misdiagnosis. In the first of this two-part review, we review the history, epidemiology, aetiology and molecular pathology of AM; in part 2 we will review diagnosis and management.
Introduction and epidemiology
Acral melanoma (AM) is a rare subtype of cutaneous malignant melanoma (MM) found on acral skin, primarily on the soles of the feet, palms of the hands, and the nails (subungual). 1, 2 Many AM lesions are further categorized as the acral lentiginous melanoma (ALM) subtype, based on their lentiginous pattern on histology. 3 The term acral refers to the location of these lesions on the hands and feet, with the majority being found on the feet. 4 Overall, AM accounts for 2-3% of all MMs. 5 Although rare, it is the most common subtype of MM found in darker-skinned populations, including those of African, 5, 6 Chinese, 7 Korean, 8 Singaporean 9 and Latin American descent. 5, [10] [11] [12] Unfortunately AM has a poor prognosis, often because of the more advanced stage of presentation at diagnosis.
1,13,14 Table 1 shows the incidence of AM among diagnoses of all cutaneous MM in different ethnic populations. Patients with darker skin phototypes are more likely to have acral melanocytic lesions than nonHispanic white patients, 15, 16 and often are unaware of the presence of these lesions. 17 AM can also be missed in fair-skinned individuals prone to amelanotic lesions. Thus, a greater emphasis on MM screening and awareness is essential in these populations to improve survival outcomes. 18 AM often occurs in older patients, and compared with other subtypes of MM, is associated with a lower incidence of familial MM and lower number of common and atypical naevi. 2 Additionally, its incidence does not correlate with lifetime sunburn or sun exposure. However, AM is associated with a higher incidence of both individual and familial history of extracutaneous cancers. 2, 19 The pathogenesis of AM remains elusive, but it has been suggested that gene alterations and/or chronic trauma to acral skin may play a role. 2 Early diagnosis of AM is important for a better prognosis but its identification is often challenging, leading to easy misdiagnosis.
In this article, we review the history, epidemiology, aetiology and molecular pathology of AM. The clinical presentation, histopathology, diagnosis and management of AM will be reviewed in part 2 of this series.
The primary database used for this article was PubMed. The search terms used included 'acral melanoma' and 'acral lentiginous melanoma' and these phrases were combined with the terms 'pathology,' and 'aetiology.' Based on the results, more specific terms, including 'KIT,' 'BRAF' and 'CCND1' were then added to the combinations.
Historical background AM was first described in 1976 by Richard J. Reed as acral lentiginous MM and subsequently included as the fourth subtype of MM. It received its name based on its tendency to be located at acral, or distal areas of the body. Many, but not all AM lesions, can be further characterized by their radial or 'lentiginous' growth phase. 20 Reed based the diagnosis on histological, intradermal features, which demonstrate diffuse proliferation of large atypical melanocytes close to the epidermal-dermal junction. This proliferation is dispersed in a lentiginous pattern with marked acanthosis and elongation of the rete ridges. 20 Additionally in 1977, Arrington et al. further described the characteristic lentiginous radial component of melanocytic proliferation, as well as the distinctive features of volar and subungual MMs. 21 
Aetiology and pathophysiology
The precise pathogenesis of AM continues to be investigated, but genetic alterations and trauma have been implicated. BRAF, NRAS, KIT and PTEN are all genes that have been well established as playing a major role in MM, but their role in the AM subtype has only recently been investigated. BRAF and NRAS are oncogenes that have been identified as the most frequently altered in MM, with BRAF mutations found in approximately 50% of tumours and NRAS mutations in approximately 20%. 22 However, the involvement of these oncogenes in the development and progression of AM has not been as well studied. It is known that BRAF mutations are more common in MMs located on skin with intermittent sun exposure (i.e. trunk), than in those located on skin with chronic exposure (i.e. face), or those with relatively low to no sun exposure, including acral and mucosal areas. 22 Conversely, NRAS mutations are more frequently found in skin with chronic sun damage. 22 Mutations in BRAF result in activation of the mitogen-activated protein kinase (MAPK) pathway, while mutations in NRAS result in activation of both MAPK and the phosphatidylinositol-3 kinase (PI3K)/Akt pathways. 22 Both the MAPK and PI3K/Akt pathways are involved in regulating cellular activity, such as proliferation, differentiation and survival, thus playing a critical role in melomagenesis. 22 The PI3K/Akt pathway plays an additional role through inactivation of the PTEN tumour suppressor gene. 22 Mutations of the KIT gene have been identified in certain invasive MMs, including AM and amelanotic AM. 23 KIT is an oncogene that encodes a transmembrane tyrosine kinase receptor, which leads to activation of the MAPK and PI3K/Akt pathways, similar to that seen with NRAS mutations. KIT mutations and/or amplifications are more commonly identified in MMs located on acral and mucosal surfaces than in MMs on intermittently sun-exposed areas. 22 Although the prevalence of KIT mutations in AM has been shown to be only 10-20%, its identification can still have an impact on therapy. 22, 24 A recent study of Swedish patients with AM showed that KIT, NRAS and BRAF mutations all occur at similar frequencies, of about 15%. 22 Another study by Torres-Cabala et al. found that in 81% of AMs, including those that were primary and metastatic, KIT was expressed by at least 5% of tumour cells. 25 In addition, the frequency of activating KIT gene mutations in AMs was 15%. The L576P mutation in exon 11 was the most frequently detected. 25 The BRAF mutations identified were significantly correlated with younger age at diagnosis, female sex and tumour location on the feet, but more studies are needed. By contrast, PTEN mutations occurred at a much lower frequency in primary AMs. Identification of these mutations is already having an impact on therapeutic interventions, particularly targeted therapy such as BRAF/ MEK inhibitors in BRAF-mutated tumours, imatinib in Table 1 Incidence of AM among all diagnoses of cutaneous melanoma in different populations.
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Incidence of AM, % In addition to the aforementioned implicated genes, amplifications of the CCND1 gene have also been identified in AM.
26 CCND1 encodes the cell cycle regulator, cyclin D1 protein, which leads to dysregulation of the cell cycle at the G1-S checkpoint.
In the 1930s, prior to elucidation of naevus cell origin, it was speculated that trauma could stimulate cutaneous nerves to transform specific cells at their nerve endings into MMs. 27 As our understanding has evolved, many studies have weakened the link between penetrative injuries and MM formation. Some suggest that trauma merely draws attention to the location, following which the melanotic lesion is noticed. 28 However, recent studies have shown that physical and mechanical stress may indeed be associated with MM development on the foot. 29, 30 Further studies may validate the causative role of stress and trauma on acral melanomagenesis.
Conclusion
AM is a rare subtype of MM, but is the most common form found in darker-skinned patients. The pathogenesis of AM is unclear, but genetic alterations, including mutations in BRAF, NRAS and KIT, have been implicated. AM has a poor prognosis because of the advanced stage of presentation on diagnosis, most likely attributable to delay or misdiagnosis. Greater awareness and screening for MM, particularly AM, in African and Asian populations is needed to improve survival outcomes.
Learning points
• AM is the most common subtype of MM found in those of African or Asian ethnicity.
• AM is found on acral skin, primarily on the soles of the feet, palms of the hand and nail beds.
• AM has a poor prognosis, often due to the more advanced stage of presentation at diagnosis, thus, a greater emphasis on MM screening and awareness is essential in darker-skinned populations to improve survival outcomes.
• KIT mutations or amplifications are more commonly identified in those MMs located on acral and mucosal surfaces than in MMs on intermittently sun-exposed areas.
• Amplifications of the CCND1 gene have been identified in AM.
